Nautilus features a structure that allows it to be used alongside an aneurysm embolisation coil. Credit: Kaneka Corporation / EndoStream Medical Ltd / Business Wire.

Japan-based Kaneka has acquired 96.8% shares in Israeli company EndoStream Medical (ESM), which manufactures cerebrovascular disease technologies.

This strategic move is aimed at bolstering the development of new medical devices, particularly for cerebrovascular treatment, including ESM’s Nautilus device for aneurysms.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

ESM’s technical expertise will be combined with Kaneka’s ‘manufacturing’ capabilities to develop the new devices.

Designed to treat cerebral aneurysms with wide openings, Nautilus gained regulatory approval in Europe last November and is expected to be approved and launched in the US market by early 2026 and in Japan in 2027.

Featuring a ‘special’ structure that allows it to be used alongside an aneurysm embolisation coil, Nautilus claims to offer a solution for challenging treatments that are not possible with existing solutions.

Kaneka’s diverse business portfolio includes devices for cardiac, peripheral vascular, and cerebrovascular diseases, as well as gastrointestinal tract disease treatments.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company’s Health Care Solution Unit, which encompasses these medical businesses, is targeting sales of Y300bn by 2030.

Its existing cerebrovascular products include the i-ED COIL for preventing subarachnoid haemorrhage caused by cerebral aneurysms and Tigertriever, a device for cerebral thrombus retrieval in stroke cases.

The acquisition of ESM is expected to further enhance Kaneka’s product range and contribute to its growth, with a sales target exceeding Y20bn by 2030.

In January 2024, Kaneka established an exclusive distribution agreement in Japan with Israel-based Rapid Medical for Tigertriever.

Tigertriever incorporates a mechanism that enables the stent to be both opened and closed, facilitating the entanglement and retrieval of neurovascular blood clots while reducing the strain on blood vessels.